Pretzel Therapeutics presented new preclinical data for PX578 at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference, highlighting the potential of the investigational small molecule to treat mitochondrial DNA depletion syndromes including POLG disease. The experimental therapy is currently in Phase 1 clinical development and is designed to activate the mitochondrial DNA polymerase POLG enzyme to restore mitochondrial DNA levels and improve cellular energy production.

The announcement underscores a growing effort within rare disease research to move beyond symptom management and toward therapies that directly target the biological drivers of mitochondrial dysfunction. In the case of POLG disease, the underlying problem lies in defective mitochondrial DNA replication, which disrupts the energy production systems that cells rely on for survival and function. By attempting to directly activate the defective enzyme responsible for mitochondrial DNA maintenance, Pretzel Therapeutics is pursuing an approach that addresses the root cause of the disorder rather than its downstream consequences.

Why restoring mitochondrial DNA levels could reshape treatment approaches for POLG disease

Mitochondrial DNA depletion syndromes represent one of the most challenging categories of rare metabolic disease because the conditions arise from fundamental defects in cellular energy production. Mutations affecting mitochondrial DNA replication or maintenance can lead to progressive failure in tissues with high energy demands, including the brain, liver, and muscles.

POLG disease is among the most severe of these conditions. Mutations in the gene encoding mitochondrial DNA polymerase gamma impair the enzyme responsible for replicating mitochondrial DNA, gradually reducing the number of functional mitochondrial genomes within cells. As mitochondrial DNA levels fall, the ability of mitochondria to generate energy through oxidative phosphorylation deteriorates.

Existing management strategies for POLG disease remain largely supportive. Clinicians currently rely on symptomatic treatments aimed at managing neurological complications, seizures, liver dysfunction, and muscle weakness. No therapy approved by regulators directly targets the genetic or enzymatic cause of mitochondrial DNA depletion in this patient population.

The investigational strategy pursued by Pretzel Therapeutics therefore reflects a broader shift in rare disease drug development toward mechanism-driven interventions. Rather than compensating for downstream damage, developers are increasingly attempting to restore the molecular pathways that sustain normal cellular function.

What PX578’s mechanism of action reveals about the emerging mitochondrial therapeutics landscape

PX578 is designed as a first-in-class activator of mitochondrial DNA polymerase POLG, an enzyme responsible for copying mitochondrial DNA during replication and repair processes. According to the company’s preclinical findings, the compound increases mitochondrial DNA levels while improving markers of cellular respiration and energy production in multiple experimental models.

If this mechanism translates successfully into human studies, it could establish a new therapeutic class focused on mitochondrial genome restoration. Such an approach differs from earlier mitochondrial medicine strategies that attempted to enhance mitochondrial function through metabolic supplements or antioxidants.

Historically, therapies targeting mitochondrial dysfunction have often struggled because they attempted to compensate for damaged energy systems rather than repair the underlying genetic defects. Supplements such as coenzyme Q10, riboflavin, or metabolic cofactors have shown limited and inconsistent benefits in mitochondrial disorders.

By contrast, the strategy behind PX578 aims to restore mitochondrial DNA copy number directly. Increasing the number of functional mitochondrial genomes within cells could theoretically allow mitochondria to regain normal energy production capacity, thereby addressing the root pathology of mitochondrial DNA depletion syndromes.

Industry observers note that such approaches could open the door to a new generation of treatments for mitochondrial diseases that have historically lacked disease-modifying options.

What the preclinical data suggest about biological activity across POLG mutations

One of the key questions facing any targeted therapy for rare genetic diseases is whether it can address multiple mutation variants rather than a narrow subset of patients. According to the data presented at the conference, PX578 demonstrated activity across several POLG mutations tested in laboratory models.

This aspect of the program could be particularly important from a clinical development perspective. POLG disease encompasses a broad spectrum of mutations that can produce varying degrees of enzyme dysfunction. A therapy capable of activating the mutant enzyme across multiple variants would significantly expand the potential patient population.

The company reported that the compound showed activity against the four most common POLG mutations, which together represent a substantial portion of known cases.

For clinicians who manage mitochondrial disease patients, such cross-mutation activity could be crucial for practical implementation. Highly mutation-specific therapies often face limited adoption because they only apply to small subgroups of patients.

If PX578 can consistently activate multiple mutant forms of the POLG enzyme, the drug could potentially serve as a broadly applicable therapy within the mitochondrial DNA depletion syndrome category.

Why the transition from preclinical success to human efficacy remains uncertain

Despite encouraging early findings, the path from preclinical success to clinical efficacy in mitochondrial disease remains highly uncertain. Rare metabolic disorders frequently involve complex systemic biology, and laboratory models may not fully replicate human disease progression.

One challenge lies in translating improvements in cellular respiration or mitochondrial DNA levels observed in experimental systems into meaningful clinical outcomes for patients. While laboratory biomarkers may show improvement, regulators and clinicians ultimately focus on functional endpoints such as neurological performance, liver function, and survival.

Another uncertainty concerns the long-term effects of altering mitochondrial DNA replication. Mitochondrial biology involves tightly regulated genetic processes, and excessive activation of replication pathways could theoretically introduce new risks if not carefully controlled.

For this reason, upcoming clinical studies will need to evaluate not only pharmacokinetics and safety but also whether the therapy produces measurable improvements in disease progression.

What Pretzel Therapeutics’ clinical roadmap suggests about development strategy

Pretzel Therapeutics initiated a Phase 1 study of PX578 in healthy volunteers in 2025 and expects to complete the study during the first half of 2026.

The company plans to move rapidly into a Phase 2 clinical trial later in the year, with the goal of generating proof-of-concept evidence in patients with POLG disease.

This development timeline reflects the urgency often associated with rare genetic diseases that lack effective treatment options. Because POLG disease can progress rapidly and lead to severe neurological and systemic complications, regulators have historically shown openness to accelerated development pathways when compelling clinical evidence emerges.

However, designing meaningful clinical endpoints for mitochondrial diseases remains a major challenge. Symptoms often progress slowly or vary widely between patients, making it difficult to demonstrate statistically significant treatment effects within conventional trial durations.

Clinical investigators will therefore closely watch how Pretzel Therapeutics structures its Phase 2 study, particularly the selection of biomarkers and patient-reported outcomes used to measure treatment benefit.

What clinicians and regulators will watch as mitochondrial therapies enter clinical testing

Several critical questions remain unresolved as the PX578 program advances toward patient trials.

First, regulators will likely examine whether increases in mitochondrial DNA levels translate into clinically meaningful outcomes. Biomarker improvement alone may not be sufficient to support regulatory approval unless accompanied by clear patient benefits.

Second, clinicians will want to understand whether the therapy works across different stages of disease progression. Many patients with mitochondrial DNA depletion syndromes are diagnosed only after significant tissue damage has already occurred.

Third, manufacturing scalability and treatment accessibility could become important considerations if the therapy proves effective. Rare disease treatments often face challenges related to pricing, reimbursement, and patient access, particularly when development costs are high.

Finally, industry observers will watch whether the mitochondrial DNA restoration strategy can extend beyond POLG disease to other mitochondrial disorders involving impaired DNA replication or maintenance.

Why the broader mitochondrial medicine field may be entering a new phase

The PX578 program reflects a broader resurgence of interest in mitochondrial medicine after decades of limited therapeutic progress. Advances in molecular biology, genetics, and cellular metabolism are now enabling drug developers to target mitochondrial processes with far greater precision.

Several biotechnology companies are exploring therapies aimed at mitochondrial DNA repair, metabolic pathway modulation, and mitochondrial gene expression control. These approaches collectively represent a shift from supportive care toward mechanistic intervention.

If one of these programs demonstrates convincing clinical efficacy, it could validate mitochondrial bioenergetics as a viable therapeutic frontier across multiple rare disease categories.

For Pretzel Therapeutics, the coming clinical trials will determine whether its POLG activation strategy can translate laboratory insights into meaningful patient benefit. The outcome of those studies will not only shape the future of PX578 but may also influence the trajectory of mitochondrial therapeutics as a whole.

  mitochondrial disorders, mitochondrial DNA depletion syndromes, mitochondrial DNA polymerase POLG, mitochondrial medicine, POLG disease, Pretzel Therapeutics, PX578, rare disease drug development